Breaking News

Financial Reports: AstraZeneca

By Gil Roth | February 6, 2014

Generics drive sales down, more layoffs planned

AstraZeneca 4Q13

4Q Revenues: $6.8 billion (-6%)

4Q Loss: $524 million (earnings of $1.5 billion in 4Q12)

FY Revenues: $25.7 billion (-8%)

FY Earnings: $2.6 billion (-60%)

Comments: For FY13, AstraZeneca's U.S. revenues fell by 9%, while Rest of World (RoW) revenues fell 4%. Crestor revenues fell by 8% in both 4Q and FY, to $1.5 billion and $5.6 billion, respectively. Onglyza reenues grew 17% in FY to $378 million, but only 6% in 4Q to $93 million. Symbicort sales were up 11% in 4Q to $976 million and 10% in FY to $3.5 billion. Generic pressure erased 39% of Seroquel sales, which dropped from $2.8 billion in FY12 sales to $1.7 billion in FY13. Brilinta sales were $92 million in 4Q, up from $75 million in 3Q13. Sales of Atacand and Seloken/Toprol-XL began to crater from generic exposure. Atacand sales fell 39% in FY to $611 million, while Seloken 4Q sales fell 32% to $170 million. Losec/Prilosec sales fell 28% in FY to $486 million. Nexium sales were flat at $3.9 billion in FY, but generics will enter the U.S. market in 2Q14. The company announced an additional $700 million in restructuring programs, which will lead to cuts of approximately 550 staffers and is projected to result in $300 million in annual benefits. In total, the company's current restructuring will cost $3.2 billion, yield annual benefits of $1.1 billion, and result in layoffs of 5,600 people.

blog comments powered by Disqus
  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • The Western API Industry

    The Western API Industry

    Dr. Enrico T. Polastro, Arthur D. Little||January 28, 2016
    Temporary reprieve or lasting recovery?

  • CMOs: A Flexibility Alternative

    CMOs: A Flexibility Alternative

    Philip K. Burns, CRO-Consulting||January 28, 2016
    A look at how to include CMOs as an option to improve overall flexibility